HOME >> BIOLOGY >> NEWS
Physicists use fractals to help Parkinson's sufferers

A new portable system for analyzing the walking patterns of people with Parkinson's disease has been developed by researchers in the US and Japan. The system, described in the Institute of Physics publication Journal of Neural Engineering, will help doctors monitor the progress of the disease in patients and so tailor their therapy and drug regime more accurately than previously possible.

Parkinson's disease is a progressive disorder of the central nervous system. Its symptoms include: uncontrollable trembling, difficulty walking, and postural problems that often lead to falls. These symptoms are usually controlled with dopamine agonist drugs. However, these can have a number of side-effects, such as jerking movements. It is also known that the body builds up a tolerance to the drug.

Understanding the nature and severity of symptoms for individual patients, which is reflected in their walking pattern, could help doctors improve a patient's quality of life, by guiding their treatment more effectively, and so reduce side-effects.

Researchers have previously tried to quantify the problems suffered by Parkinson's patients by studying their gait. Now, Masaki Sekine, Metin Akay, and Toshiyo Tamura, of the Department of Gerontechnology, National Institute for Longevity Sciences, in Aichi, Japan and Thayer School of Engineering, New Hampshire USA, working with their colleagues at the Fujimoto Hayasuzu Hospital, in Miy azaki, Japan, have devised a portable system based on a sensor placed on the patient's body that measures movements in three dimensions. The readings from this sensor, known as a tri-axial accelerometer, are fed to a computer, together with measurements of the patients walking speed, and analysed using a fractal system.

Fractals are usually associated with irregular geometric objects that look the same no matter what scale they are viewed at: clouds, branching trees, rugged coastlines, rocky mountains, are all examples of fracta
'"/>

Contact: David Reid
david.reid@iop.org
207-470-4815
Institute of Physics
2-Feb-2004


Page: 1 2

Related biology news :

1. Physicists reveal first nanoflowers
2. Physicists Find Simple Solution To Great-And-Small Mystery
3. TANGO: towards faster prognosis of Alzheimers and Parkinsons diseases?
4. New genetic research demonstrates possible cause of inherited form of Parkinsons disease
5. Study sheds new light on genetic risk for Parkinsons disease
6. Single gene mutation muddying Parkinsons risk forecasts
7. Ritalin may improve Parkinsons symptoms, OHSU study says
8. Parkinsons disease genetic study progresses with $8 million grant
9. PDF invites scientists pursuing Parkinsons research to apply for funding
10. Yeast model yields insights into Parkinsons disease
11. Yeast helps researchers better understand Parkinsons mystery

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Physicists use fractals help Parkinson sufferers

(Date:3/23/2015)... 2015   HOYOS Labs , a leading global ... that the Company will demonstrate multiple biometrics-based technologies under ... at Connect:ID on March 23 through 25, 2015, in ... highlight the IEEE Biometric Open Protocol Standard; free biometrics-based ... access control system. BOPS was invented by HOYOS Labs ...
(Date:3/23/2015)... Mar. 23, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... the growing mobile commerce market, announces its biometric payment technology, ... on CNBC television starting March 30 th . ... in New York markets. ... are excited about our new ad campaign following the recent ...
(Date:3/20/2015)... and Markets ( http://www.researchandmarkets.com/research/rswjb4/hand_geometry ) has announced the ... Report" report to their offering. This report ... The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... Annual estimates and forecasts are provided for the period ...
Breaking Biology News(10 mins):HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4
(Date:4/16/2015)... 2015 OncoTAb, Inc., ... Charlotte) spin-out company, announced today the appointment of ... as Chief Operating Officer (COO). Cooper brings to ... developing clinical diagnostic and biotechnology platforms in the ... Cooper’s extensive career transcends the field of medical ...
(Date:4/16/2015)...  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" ... with G-treeBNT (ReGenTree LLC) has retained Ora, Inc. ... the orphan disorder, neurotrophic keratopathy (NK), and a ... (DES) in the U.S.  Both trials will be ... Each of these eye disorders was being targeted ...
(Date:4/16/2015)... 16, 2015  AnaptysBio, Inc., a leader in ... today announced the advancement of its first-in-class ... studies. The Company,s anti-IL-36R therapeutic antibody, called ... pustular psoriasis (GPP), an orphan systemic inflammatory ... wholly owned within AnaptysBio,s proprietary antibody pipeline ...
(Date:4/16/2015)... Switzerland , April 16, 2015 /PRNewswire/ ... Debiopharm Group ™ , a Swiss-based global biopharmaceutical ... medical needs as well as companion diagnostics, ... investigational compounds Debio 1143 (SMAC mimetic) and Debio 1347/CH5183284 ... the 2015 Annual meeting of the American Association for Cancer Research ...
Breaking Biology Technology:OncoTAb Names Dr. David L. Cooper as COO 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5AnaptysBio Advances First-In-Class Anti-IL-36 Receptor Antibody Program To Treat Orphan Inflammatory Disease 2Debiopharm International SA Announces Results of 2 Key Oncology Programs at 2015 AACR Conference 2Debiopharm International SA Announces Results of 2 Key Oncology Programs at 2015 AACR Conference 3
Cached News: